Vaccine News and Research RSS Feed - Vaccine News and Research

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.
Researchers successfully test new anti-cocaine vaccine in primates

Researchers successfully test new anti-cocaine vaccine in primates

Researchers at Weill Cornell Medical College have successfully tested their novel anti-cocaine vaccine in primates, bringing them closer to launching human clinical trials. [More]

UNM Cancer Center to participate in Phase 3 clinical trial of novel treatment for men with prostate cancer

The University of New Mexico Cancer Center is among a few select institutions nationwide participating in a Phase 3 clinical trial studying a novel treatment for men with newly diagnosed, localized prostate cancer. [More]
Longer looks: A wife's Alzheimer's, Obamacare and workers' hours, doctors and drug companies

Longer looks: A wife's Alzheimer's, Obamacare and workers' hours, doctors and drug companies

When his wife got Alzheimer's disease, lawyer Ken Chiate invested all his hopes in an unorthodox treatment. Nothing, it seems, could make him give up on it. ... Jeannette's difficulties seemed to emerge out of nowhere. She couldn't grasp the rules of a dice game. She kept asking questions her husband had just answered. ... in 2001, at age 58, she was diagnosed with mild cognitive impairment. As months and years passed, she fell into an angry haze that was determined to be Alzheimer's disease. [More]
National Institutes of Health names University of Rochester a Center for AIDS Research

National Institutes of Health names University of Rochester a Center for AIDS Research

The University of Rochester was named a Center for AIDS Research by the National Institutes of Health, a designation that infuses $7.5 million into HIV/AIDS work across the University and places it amongst the best in the nation for research to improve the prevention, detection and treatment of the disease. [More]
Study shows malaria transmission can be controlled by using bacteria

Study shows malaria transmission can be controlled by using bacteria

Mosquitoes are deadly efficient disease transmitters. Research conducted at Michigan State University, however, demonstrates that they also can be equally adept in curing diseases such as malaria. [More]

Scientists identify new class of immune cells that suppress genital herpes

Fred Hutchinson Cancer Research Center and University of Washington scientists have identified a class of immune cells that reside long-term in the genital skin and mucosa and are believed to be responsible for suppressing recurring outbreaks of genital herpes. [More]
Researchers discover potential treatment for deadly, drug-resistant bacterial infections

Researchers discover potential treatment for deadly, drug-resistant bacterial infections

Through the serendipity of science, researchers at the University of Pittsburgh have discovered a potential treatment for deadly, drug-resistant bacterial infections that uses the same approach that HIV uses to infect cells. [More]
Scientists identify TR4 protein that drives the formation of pituitary tumors in Cushing's disease

Scientists identify TR4 protein that drives the formation of pituitary tumors in Cushing's disease

Scientists at the Salk Institute for Biological Studies have identified a protein that drives the formation of pituitary tumors in Cushing's disease, a development that may give clinicians a therapeutic target to treat this potentially life-threatening disorder. [More]
Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100. [More]
New VLP vaccine candidate produced for H7N9 virus

New VLP vaccine candidate produced for H7N9 virus

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it has successfully produced a new VLP vaccine candidate for the H7N9 virus that is responsible for the current influenza outbreak in China. [More]

TSRI, Janssen to collaborate on focused research projects in infectious disease area

The Scripps Research Institute today announced a five-year agreement with Janssen Pharmaceuticals, Inc. to collaborate on focused research projects in the infectious disease area, with the initial project targeting the influenza virus. [More]
New NTD Special Envoys to focus on eliminating NTD primarily on LAC region

New NTD Special Envoys to focus on eliminating NTD primarily on LAC region

Today, the Global Network for Neglected Tropical Diseases, a major initiative of the Sabin Vaccine Institute, announced His Excellency, President Alvaro Arz- Irigoyen of Guatemala (1996-2000), His Excellency, President Ricardo Lagos Escobar of Chile (2000-2006) and former Pan American Health Organization Director Dr. Mirta Roses Periago as the organization's newest Neglected Tropical Disease Special Envoys. [More]
Study says influenza immunization is safe in children with IBD

Study says influenza immunization is safe in children with IBD

Influenza immunization rates in children with inflammatory bowel disease (IBD) are low despite its safety according to a new study by researchers at the Institute for Clinical Evaluative Sciences (ICES), Children's Hospital of Eastern Ontario (CHEO), the Ottawa Hospital Research Institute (OHRI), and the University of Ottawa. [More]

Study provides additional data on why RV144 vaccine failed to protect more people

Continuing analysis of an HIV vaccine trial undertaken in Thailand is yielding additional information about how immune responses were triggered and why the vaccine did not protect more people. [More]

TSRI announces five-year agreement with Janssen to research on influenza virus

The Scripps Research Institute (TSRI) today announced a five-year agreement with Janssen Pharmaceuticals, Inc. (Janssen) to collaborate on focused research projects in the infectious disease area, with the initial project targeting the influenza virus. [More]
Aeras receives grant to support the development of vaccines against TB, HIV and malaria

Aeras receives grant to support the development of vaccines against TB, HIV and malaria

Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford and Okairos, a biopharmaceutical company specializing in T-cell vaccines, today announced a $2.9 million grant to Aeras in support of a collaboration among the three parties to support the development of vaccines against tuberculosis, HIV and malaria. [More]
Neuroperspective reviews status and prospects of therapeutics for Parkinson's disease

Neuroperspective reviews status and prospects of therapeutics for Parkinson's disease

NI Research, the leading publisher of independent research on the neurotherapeutics industry, has released the May issue of NeuroPerspective, which reviews the status and prospects of therapeutics for Parkinson's. [More]

Program on Medicine and Religion selects faculty scholars

The University of Chicago Medicine's Program on Medicine and Religion has selected its second round of faculty scholars whose focus will be on the relationship between a physician's spirituality and their ability to deal with the pressures of practicing medicine. [More]

With GPEI plan, polio eradication may finally be within reach

"After 25 years of remarkable achievements and sometimes harrowing setbacks, a successful conclusion to global polio eradication could finally be within reach," Nellie Bristol, a fellow with the Global Health Policy Center at the Center for Strategic and International Studies in Washington, D.C., and J. Stephen Morrison, senior vice president and director of the Global Health Policy Center at CSIS, write in a CSIS commentary. [More]
Researchers reveal how Ebola evades human immune response

Researchers reveal how Ebola evades human immune response

Researchers have discovered the mechanism behind one of the Ebola virus' most dangerous attributes: its ability to disarm the adaptive immune system. [More]